William Blair Reaffirms Market Perform Rating for Kezar Life Sciences (NASDAQ:KZR)

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “market perform” rating restated by investment analysts at William Blair in a report issued on Wednesday,RTT News reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, October 14th.

Kezar Life Sciences Price Performance

Shares of KZR opened at $7.52 on Wednesday. The stock has a 50 day moving average price of $7.16 and a 200 day moving average price of $6.85. Kezar Life Sciences has a 52-week low of $5.20 and a 52-week high of $11.35. The company has a quick ratio of 9.58, a current ratio of 7.65 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Tuesday, August 13th. The company reported ($2.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.20) by $0.40. Equities analysts predict that Kezar Life Sciences will post -11.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Affinity Asset Advisors LLC purchased a new position in Kezar Life Sciences in the first quarter valued at about $1,588,000. Stonepine Capital Management LLC purchased a new stake in shares of Kezar Life Sciences during the 2nd quarter valued at about $630,000. Acadian Asset Management LLC lifted its position in Kezar Life Sciences by 42.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company’s stock worth $1,613,000 after acquiring an additional 534,203 shares in the last quarter. Acuitas Investments LLC boosted its holdings in Kezar Life Sciences by 42.8% in the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after acquiring an additional 295,956 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Kezar Life Sciences in the second quarter valued at approximately $63,000. Hedge funds and other institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.